Table 4 Final clinical outcome (FCO) and times to onset of symptom relief (OSR) and achievement of FCO

FCO available

21

Any outcome

NA

NA

NA

18

Fully resolved

3

Discharged without complete resolution

Median time to OSR

21

All

1.34 (1.00–5.63)

0.8^b

0.04*

10

HAE vs natural history

1.13 (0.75–NE)

0.8^b

3.5^b

0.34

0.10

9^a

ACEI-induced (n = 9) vs. natural history

4.86 (2.17–NE)

0.8^b

1.6^c

0.01*

0.29

14

Face/oropharolarynx symptoms present

2.17 (0.83–NE)

0.7^b

0.09

7

Face/oropharolarynx symptoms not present

1.00 (0.75–NE)

0.8^b

0.45

Median time to FCO

21

All groups

7.75 (2.5–43.41)

8.0^b

1.00

10

HAE vs natural history

3.50 (1.83–NE)

8.0^b

36.0^b

0.11

0.02*

9^a

ACEI-induced vs. natural history

19.53 (8.13–NE)

4.5^b

4.0^c

0.18

0.18

14

Face/oropharolarynx symptoms present

8.93 (4.67–73.28)

6.0^b

0.42

7

Face/oropharolarynx symptoms not present

2.18 (1.83–NE)

8.0^b

0.45

Median time from attack onset to icatibant dose

10

HAE

9.58 (8.20–NE)

Pairwise

0.80

9

ACEI-induced

16.53 (4.25–NE)